Summit Therapeutics surges after AstraZeneca takes a $2 billion equity stake
+5.88% to $16.39 from $15.48
What moved SMMT
- AstraZeneca agreed to make a $2 billion strategic equity investment in Summit Therapeutics, sending Summit shares sharply higher in premarket and regular trading.
- The investment underscores continued large-pharma interest in Summit’s clinical pipeline, which has drawn attention from bigger drugmakers looking to bolster oncology assets.
Sources: Yahoo Finance